Intelligent Bio Solutions Reports 28% Revenue Growth in Q1
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Source: NASDAQ.COM
- Significant Revenue Growth: Intelligent Bio Solutions reported $1.11 million in revenue for Q1 2025, up from $0.8 million year-over-year, reflecting a more than 28% increase driven by rising demand for drug testing solutions in safety-critical sectors like logistics and transport.
- Financing for Expansion: The company closed a $10 million private placement in early 2026 at market price under Nasdaq rules, bolstering its cash position and providing capital to accelerate commercialization, expand distribution partnerships, and advance R&D initiatives.
- Fingerprint Drug Testing Platform: Its flagship Intelligent Fingerprinting Drug Testing System offers non-invasive screening through sweat collected from fingerprints, delivering results in minutes and detecting substances like opiates, methamphetamine, cocaine, and cannabis, focusing on impairment within a 16-24 hour window.
- Increased Market Attention: With improving quarterly revenue, fresh financing, and growing adoption of its fingerprint testing technology, Intelligent Bio Solutions saw its stock surge by 23% in pre-market trading, indicating strong market interest in its growth potential.
Analyst Views on INBS
About INBS
Intelligent Bio Solutions Inc. is a medical technology company focused on developing and delivering intelligent, rapid, non-invasive testing and screening solutions. Its segment includes Commercially available Intelligent Fingerprinting Products and Development Stage Biosensor Platform Technology. Its product portfolio includes Intelligent Fingerprinting Platform that analyzes fingerprint sweat using a one-time cartridge and portable handheld reader, and a two-part system that consists of non-invasive, fingerprint sweat-based diagnostic testing products designed to detect drugs of abuse including opiates, cocaine, methamphetamines, benzodiazepines, cannabis, methadone, and buprenorphine. The Biosensor Platform is designed to detect multiple biological analytes by substituting the top enzyme layer of the biosensor to suit each analyte and to develop a range of Point of Care Tests, including the modalities of clinical chemistry, immunology, tumor markers, allergens, and endocrinology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
